Abstract Number: 790 • 2018 ACR/ARHP Annual Meeting
Gastrointestinal Symptom Burden and Quality of Life in Systemic Sclerosis: Understanding the Role of Diet
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease affecting multiple organ systems including vascular, musculoskeletal, cardiac, renal, pulmonary, and gastrointestinal (GI). 90% of SSc…Abstract Number: 791 • 2018 ACR/ARHP Annual Meeting
Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
Background/Purpose: Studies from our laboratory and others have shown thrombin to be a fibrogenic mediator implicated in the pathogenesis of ILD, including scleroderma-associated ILD (SSc-ILD).…Abstract Number: 792 • 2018 ACR/ARHP Annual Meeting
Evaluation of Esophageal Dysmotility in Systemic Sclerosis: Clinical VALUE of Computed Tomography
Background/Purpose: Esophageal dysmotility is common in Systemic Sclerosis (SSc), affecting 50-80% of patients, usually associated with poor prognosis. SSc leads to atrophy and fibrosis of…Abstract Number: 793 • 2018 ACR/ARHP Annual Meeting
Clinical Associations of Anti-U11/U12 (RNPC-3) Autoantibodies in Patients with Systemic Sclerosis
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important role in the diagnosis and…Abstract Number: 794 • 2018 ACR/ARHP Annual Meeting
Identification of an Immunodominant Epitope on Rnpc-3 As a Target of Autoantibodies in Patients with Systemic Sclerosis
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important role in the diagnosis and…Abstract Number: 795 • 2018 ACR/ARHP Annual Meeting
Frequency and Clinical Associations of Rare Antibodies in a Large Connective Tissue Disease Cohort
Background/Purpose: Connective tissue diseases (CTDs) are characterised by specific autoantibodies which are useful for diagnosis. Rare antibodies have been described in CTDs in several case…Abstract Number: 796 • 2018 ACR/ARHP Annual Meeting
Demographic and Clinical Features of Systemic Sclerosis Patients with Anti-U1RNP Antibodies: A European Scleroderma Trials and Research (EUSTAR) Analysis
Background/Purpose: Anti-U1RNP antibodies can be detected in patients with systemic sclerosis (SSc). However, their prevalence and clinical correlation with organ-specific complications have not been well…Abstract Number: 797 • 2018 ACR/ARHP Annual Meeting
Absolute Reduction of Peripheral CD4+ Regulatory T Cells in Patients with Systemic Sclerosis and Its Restoration By Short-Term and Low Dose IL-2 Treatment
Background/Purpose: The aim of the present study was to investigate whether the imbalance of CD4+ T subsets can be corrected by supplementing low dose interleukin -2 (IL-2).Methods:…Abstract Number: 798 • 2018 ACR/ARHP Annual Meeting
Predominant Fasciitis and Mild Intramuscular Edema on Muscle Magnetic Resonance Imaging in Scleroderma-Associated Myopathy
Background/Purpose: Skeletal myopathy in systemic sclerosis is poorly defined. The spectrum of muscle histopathology in systemic sclerosis has been previously studied and shown to be…Abstract Number: 799 • 2018 ACR/ARHP Annual Meeting
Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the Eustar Database
Background/Purpose: Systemic sclerosis (SSc) carries a high risk for interstitial lung disease (ILD). Patients with SSc-ILD are prone to develop progressive lung fibrosis, but there…Abstract Number: 800 • 2018 ACR/ARHP Annual Meeting
Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD
Background/Purpose: Systemic Sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of skin and internal organs with an estimated worldwide prevalence of 110-430 cases/million.…Abstract Number: 801 • 2018 ACR/ARHP Annual Meeting
Cardiac Autonomic Modulation at Rest and during Orthostatic Stress in Systemic Sclerosis Patients
Background/Purpose: Autonomic dysfunction is a marker of myocardial involvement in systemic sclerosis (SSc) and heart rate variability (HRV) is impaired in SSc patients (1). The…Abstract Number: 802 • 2018 ACR/ARHP Annual Meeting
Prognostic Significance of Bicaudal D2 Antibodies in Sistemic Sclerosis (SSc) Patients
Background/Purpose: Antibodies (Ab) toward Bicaudal D homolog 2 (BlCD2) can be found in 25% of Systemic Sclerosis (SSc) sera, mostly in association with anti-centromere (ACA)…Abstract Number: 803 • 2018 ACR/ARHP Annual Meeting
Treating Interstitial Lung Disease and Skin Involvement in Systemic Sclerosis with Oral Versus Intravenous Cyclophosphamide: Preliminary Efficacy and Safety Data from 2 Randomized Clinical Trials and 1 Registry
Background/Purpose: Two randomized controlled trials showed modest but significant effects for oral (po) CYC ( superior to placebo and equal to mycophenolate mofetil). A number…Abstract Number: 804 • 2018 ACR/ARHP Annual Meeting
Prevalence of Echocardiographic Abnormalities in Patients with Systemic Sclerosis
Background/Purpose: To determine the prevalence of echocardiographic abnormalities and to identify associated clinical and laboratory features in a large systemic sclerosis (SSc) cohort. Methods: The…
